Prognostic Factors and a Polymetastasis-Free Survival Nomogram in Oligometastatic Head and Neck Squamous Cell Carcinoma Treated with Local Ablative Therapy.
- 1Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
- 2Department of Otolaryngology-Head and Neck Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
- 3Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Abstract
Evidence supporting metastasis-directed local ablative therapy (LAT) in head and neck squamous cell carcinoma (HNSCC) with oligometastatic disease (OMD) is limited. We retrospectively reviewed 93 patients with HNSCC who developed OMD and received LAT to all metastatic sites between 2006 and 2025. Clinical variables, sarcopenia, nutritional status, and inflammatory indices were evaluated as potential predictors of overall survival (OS), progression-free survival (PFS), polymetastasis-free survival (PMFS), and polymetastatic conversion (PC). An exploratory prognostic nomogram for PMFS was developed to inform treatment decision-making. After a median follow-up of 28.2 months, the 3-year OS and PMFS rates were 67.2% and 51.7%, respectively. Local failure occurred in 9 patients, while disease progression was predominantly distant. An HPV-positive oropharyngeal primary tumor was associated with improved OS and PMFS, whereas non-lung metastatic sites were adverse prognostic factors for PFS, and having two or more metastases was adverse for PC. Lower serum albumin levels correlated with worse OS and PFS, and an increasing systemic immune-inflammation index (SII) showed borderline significance for OS and PMFS. A PMFS nomogram based on four clinical parameters achieved an optimism-corrected concordance index of 0.66. Long-term survival and high local control were observed in this selected cohort of HNSCC patients with OMD treated with LAT. Tumor type, metastatic site, tumor burden, and host nutritional and inflammatory indices were associated with survival and progression to PC.
Related
- Conditional survival and dynamic prognostic nomogram for histologically defined anaplastic ganglioglioma: a SEER-based analysis
- Prognostic Model for Survival After Upfront R0 Gastrectomy in Peritoneal Oligometastatic Gastric Cancer.
- Early Prognostic Value of the Freiburg Index of Post-Transjugular Intrahepatic Portosystemic Shunt Survival in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation
- Prognostic impact of the preoperative Naples prognostic score on overall and progression-free survival in surgically treated oral squamous cell carcinoma: A retrospective cohort study from a Taiwanese medical center.
- Analysis of prognostic factors for survival after curative resections of clear-cell renal cell carcinoma based on Bayesian networks
BibTeX
@article{shin2026prognostic,
title = {{Prognostic Factors and a Polymetastasis-Free Survival Nomogram in Oligometastatic Head and Neck Squamous Cell Carcinoma Treated with Local Ablative Therapy.}},
author = {Young Seob Shin and Si Yeol Song and Seung Hoon Han and Minsu Kwon and Yoon Se Lee and Young Ho Jung and Seung-Ho Choi and Seyoung Seo and Sung-Bae Kim and Sang-Wook Lee},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = sep,
doi = {10.3390/curroncol33100585},
url = {https://europepmc.org/article/MED/42930152},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prognostic Factors and a Polymetastasis-Free Survival Nomogram in Oligometastatic Head and Neck Squamous Cell Carcinoma Treated with Local Ablative Therapy.
AU - Young Seob Shin
AU - Si Yeol Song
AU - Seung Hoon Han
AU - Minsu Kwon
AU - Yoon Se Lee
AU - Young Ho Jung
AU - Seung-Ho Choi
AU - Seyoung Seo
AU - Sung-Bae Kim
AU - Sang-Wook Lee
PY - 2026
DA - 2026/09/29
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100585
UR - https://europepmc.org/article/MED/42930152
AB - Evidence supporting metastasis-directed local ablative therapy (LAT) in head and neck squamous cell carcinoma (HNSCC) with oligometastatic disease (OMD) is limited. We retrospectively reviewed 93 patients with HNSCC who developed OMD and received LAT to all metastatic sites between 2006 and 2025. Clinical variables, sarcopenia, nutritional status, and inflammatory indices were evaluated as potential predictors of overall survival (OS), progression-free survival (PFS), polymetastasis-free survival (PMFS), and polymetastatic conversion (PC). An exploratory prognostic nomogram for PMFS was developed to inform treatment decision-making. After a median follow-up of 28.2 months, the 3-year OS and PMFS rates were 67.2% and 51.7%, respectively. Local failure occurred in 9 patients, while disease progression was predominantly distant. An HPV-positive oropharyngeal primary tumor was associated with improved OS and PMFS, whereas non-lung metastatic sites were adverse prognostic factors for PFS, and having two or more metastases was adverse for PC. Lower serum albumin levels correlated with worse OS and PFS, and an increasing systemic immune-inflammation index (SII) showed borderline significance for OS and PMFS. A PMFS nomogram based on four clinical parameters achieved an optimism-corrected concordance index of 0.66. Long-term survival and high local control were observed in this selected cohort of HNSCC patients with OMD treated with LAT. Tumor type, metastatic site, tumor burden, and host nutritional and inflammatory indices were associated with survival and progression to PC.
SN - 1198-0052
SN - 1718-7729
ER -